Business Context and Reporting Period
Company: Coherus BioSciences, Inc. (CHRS)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Coherus is a commercial-stage biopharmaceutical company focused on immunotherapies for cancer. Its portfolio historically included UDENYCA (a biosimilar to Neulasta), LOQTORZI (a PD-1 inhibitor for nasopharyngeal carcinoma), and recently divested franchises YUSIMRY and CIMERLI. The company is transitioning to a focused immuno-oncology strategy centered on LOQTORZI and its pipeline (casdozokitug, CHS-114).
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Total Net Revenue | $267.0 million | $257.2 million |
| Net Income (Loss) | $28.5 million | ($237.9 million) |
| Gross Margin | 56% | 38% |
| Operating Cash Flow | ($20.4 million) | ($174.9 million) |
| Cash & Equivalents (Dec 31, 2024) | $126.0 million | $102.9 million |
| Total Debt (Principal) | $268.7 million | $480.0 million |
Note: 2024 Net Income includes a $176.6 million net gain from the sale of the CIMERLI and YUSIMRY franchises. Excluding these gains, the company reported an operating loss.
Material Changes vs. Prior Period
- Revenue Composition: UDENYCA revenue increased to $206.0 million (from $127.1 million in 2023) driven by the launch of UDENYCA ONBODY, despite a Q4 supply interruption. LOQTORZI revenue grew to $19.1 million following its January 2024 launch. Revenue from CIMERLI and YUSIMRY ceased in 2024 following their divestiture.
- Profitability: The company returned to net income in 2024 ($28.5 million) compared to a net loss of $237.9 million in 2023. This reversal was primarily driven by the $176.6 million gain on sale transactions (CIMERLI and YUSIMRY) and a reduction in operating expenses.
- Debt Reduction: The company repaid $250.0 million in 2027 Term Loans in May 2024. It entered into a new $38.7 million 2029 Term Loan and a Revenue Purchase and Sale Agreement (liability of ~$28.7 million net carrying value). The $230.0 million 2026 Convertible Notes remain outstanding.
- Supply Chain: A temporary supply interruption of UDENYCA occurred in Q4 2024 due to third-party contract manufacturer capacity constraints, impacting sales volume. Production resumed in November 2024.
Guidance, Outlook, and Risks
- UDENYCA Divestiture: On December 2, 2024, Coherus agreed to sell the UDENYCA franchise to Intas Pharmaceuticals for $483.4 million in cash (including inventory), plus potential earnouts of $75.0 million. Closing is expected in Q1/Q2 2025. Proceeds will be used to repay the 2026 Convertible Notes and buy out royalty obligations.
- Strategic Shift: Post-divestiture, the company will focus exclusively on LOQTORZI and its immuno-oncology pipeline. Future financial reporting will likely present UDENYCA, CIMERLI, and YUSIMRY as discontinued operations.
- Internal Control Weakness: Management identified a material weakness in internal controls related to the documentation and review of inventory account reconciliations. This resulted in an adverse opinion from auditors on internal controls, though the financial statements received an unqualified opinion.
- Risks: Key risks include the failure to close the UDENYCA sale, continued supply chain disruptions, the commercial success of LOQTORZI in a competitive market, and the ability to achieve profitability without the high-volume biosimilar revenue stream.
Investor Verification Checklist
- UDENYCA Sale Closing: Verify the closing date and final consideration received from Intas Pharmaceuticals in Q1/Q2 2025 filings.
- Debt Repayment: Confirm the full repayment of the $230.0 million 2026 Convertible Notes using sale proceeds.
- LOQTORZI Commercialization: Monitor LOQTORZI sales growth and market share in nasopharyngeal carcinoma (NPC) to assess the viability of the post-divestiture business model.
- Internal Controls Remediation: Review subsequent filings for progress on remediating the material weakness in inventory reconciliation controls.
- Supply Chain Stability: Confirm that the new packaging and labeling CMO for UDENYCA has received FDA authorization and is supplying product without interruption prior to the sale closing.